(VSTM) Verastem, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VSTM) Verastem, Inc. Complete Analysis Pack
See the Bigger Picture
This Verastem, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the analysis, so you can inspect the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Avutometinib plus defactinib, recurrent LGSOC
Avutometinib plus defactinib is Verastem, Inc.'s Star asset and lead program, with recurrent LGSOC as a rare niche and limited options. In the phase 2 RAMP 201 study, the combo produced a 44% objective response rate and median progression-free survival of 22 months, making it the pipeline's main value driver. It is the clearest shot at a future market leader and the core of Verastem, Inc.'s growth case.
VS-6766 RAF/MEK clamp, 1 asset platform
VS-6766 is Verastem, Inc.'s core Star asset: a dual RAF/MEK clamp that blocks MEK kinase activity and also stops RAF from phosphorylating MEK, giving it clear differentiation in the KRAS/MAPK oncology space.
That mechanism supports a broad combo strategy and makes the program highly strategic as Verastem's 1-asset platform, with outsized value if late-stage data convert into approval.
Its BCG "Star" profile fits a high-growth, high-focus asset that can anchor future revenue, not just pipeline optionality.
RAMP 201, 2-part randomized study
RAMP 201 is an adaptive, multicenter, randomized, open-label study of VS-6766 alone and with defactinib in recurrent low-grade serous ovarian cancer. It is the main late-stage evidence driver for Verastem, Inc., so it sits in the Stars bucket of the BCG matrix. The trial’s two-part design supports clearer efficacy readouts and a stronger path to value creation.
Defactinib, oral FAK inhibitor
Defactinib is Verastem’s lead partner drug: an oral small-molecule focal adhesion kinase inhibitor used across avutometinib-based regimens. Its biggest value is combination depth, since the pair won U.S. FDA approval in 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer, giving the franchise a sharper commercial profile.
- Oral FAK inhibitor
- Core combo backbone
- 2025 FDA-approved regimen
Chugai rights, development to commercialization
Verastem’s Chugai deal gives Chugai rights to develop, commercialize, and manufacture VS-6766-based products, which is strong external validation for the program. A reported upfront payment of $40 million and potential milestones of up to $600 million-plus show real pharma interest in the asset. That kind of partner backing lifts VS-6766’s BCG "Star" case because it expands global reach without Verastem funding all execution alone.
- Chugai holds development, commercialization, and manufacturing rights.
- Upfront cash: $40 million.
- Milestones: up to $600 million-plus.
- Supports global upside for VS-6766.
Verastem’s FDA Win Sets Up a Real Revenue Runway
Verastem, Inc.'s Star is avutometinib plus defactinib in recurrent LGSOC: 44% objective response rate and 22-month median PFS in RAMP 201 support strong growth. The pair won U.S. FDA approval in 2025, giving the franchise real revenue potential. Chugai also paid $40 million upfront, with up to $600 million-plus in milestones.
| Star asset | Key data |
|---|---|
| Avutometinib plus defactinib | 44% ORR; 22-month PFS; 2025 FDA approval |
| Chugai deal | $40 million upfront; up to $600 million-plus milestones |
What is included in the product
Detailed Word Document
Verastem, Inc. BCG Matrix shows where to invest, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
BCG Matrix snapshot for Verastem, Inc. to quickly spot growth, cash, and risk hotspots.
Reference Sources
Verastem, Inc. Reference Sources provide a clear, credible trail that supports fast due diligence and more confident decisions.
Cash Cows
0 approved products
Verastem, Inc. has 0 approved products, so it has no true cash cow in the classic BCG sense. As an emerging biopharma, it is still in the cash-burning development stage, with revenue from approved drugs at zero and spending tied to R&D and clinical work. That means its portfolio is not generating stable cash; it is still consuming capital.
Chugai licensing economics
Chugai is Verastem, Inc.'s closest asset-linked cash stream, but it is still a support line, not a full franchise. License deals can bring upfront cash, milestones, and royalties, and royalties in biopharma often run in the low-single-digit to mid-teens range; that means the upside is real, but it stays contingent on partner progress, not Verastem's own sales engine.
Pfizer FAK agreement
In 2025/2026, Verastem’s FAK program reflects partner-sourced R&D: the Pfizer license gives access to built assets while limiting upfront discovery spend. That makes it a capital-light funding model, but not a true Cash Cow because value depends on milestone and royalty economics, not steady product sales. It lowers internal burn, but it does not yet generate durable operating cash.
Amgen collaboration support
Verastem, Inc.’s Amgen collaboration helps fund the RAMP 203 combo study, so it fits a Cash Cows label only in a support sense, not as a real product cow. The value is partner-backed development, which can ease R&D cash pressure and lower dilution risk. It does not produce steady sales like an approved drug, so the cash impact stays episodic.
- Supports RAMP 203 development
- Reduces funding strain
- Not recurring product cash flow
Non-dilutive partner funding
Verastem, Inc. has no commercial product sales, so non-dilutive partner funding is its main cash stabilizer. These deals help cover R&D while the company advances late-stage trials, so they act more like financing support than a mature product cash engine.
In its latest filings, Verastem still reported operating losses and continued to fund studies in 2025, making partner cash a key offset to trial spend. That matters because each dollar of external support reduces pressure on equity raises and helps extend runway.
- Partner cash supports clinical development.
- No product revenue, so cash stays fragile.
- Funding is non-dilutive, not sales-driven.
- It bridges R&D until commercialization.
Verastem Burns Cash, It Doesn’t Harvest It
Verastem, Inc. has no true Cash Cows because it has 0 approved products and no product revenue. Its only cash support comes from partner deals and collaborations, which help fund R&D but do not create steady operating cash. So the portfolio still burns cash, it does not harvest it.
| Item | Cash Cow? | Impact |
|---|---|---|
| Approved products | No | 0 revenue |
| Partner funding | Partial | Non-dilutive support |
| Clinical assets | No | Cash burn |
Full Version Awaits
Verastem, Inc. Reference Sources
This Verastem, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No placeholders or demo pages—just the full, professionally formatted report. Once purchased, it’s ready for immediate download and use in your analysis, presentations, or strategy work.
Dogs
0 marketed brands
Verastem, Inc. had 0 marketed brands, and no approved commercial product was disclosed, so it does not have a classic Dog in the BCG sense. The Dog quadrant is effectively empty because the Company is still pre-commercial and has no weak, declining brand to classify. That makes the point simple: no product sales means no legacy dog asset to manage or divest.
0 recurring product revenue
Verastem, Inc. had 0 recurring product revenue in FY2025 and FY2026, so there is no low-growth sales base to harvest. Without an approved product, there is also no brand with declining market share to divest. This is a company-stage gap, not a mature-product decline; Verastem reported no product sales while it kept funding pipeline work with about $144 million in cash and equivalents at year-end 2025.
No legacy commercial franchise
Verastem, Inc. has no legacy commercial franchise to drag on the Dogs side of the BCG Matrix because it is still an oncology development company, not a mature drug seller. Its value is tied to experimental assets, so the main risk is pipeline failure, not declining sales from older products. That also means there is no aging marketed drug base generating the kind of low-growth, low-share cash flow that usually defines a Dog.
No high-volume mature indication
Verastem, Inc. has no clear "dog" asset because its disclosed programs sit in rare or biomarker-defined cancers, not in a large, mature mass market. Its lead focus includes low-grade serous ovarian cancer, which is only about 1% to 2% of ovarian cancers, so the franchise is clinically important but not high-volume.
- No exhausted consumer-style market
- Rare, biomarker-driven cancer focus
- LGSC is ~1%-2% of ovarian cancers
No divestiture candidate disclosed
Verastem, Inc. has no disclosed divestiture candidate because it has no marketed product generating weak returns; the business is still centered on clinical-stage assets and partnership structures. In BCG terms, any underperforming program would be a pipeline call, not a classic "dog" tied to revenue drag. With no commercial franchise, the main capital use remains R&D, not a low-return product line.
- No public commercial "dog" is identified.
- Assets remain in trials and partnerships.
- Weak programs would be pipeline cuts.
Verastem Has No “Dog” Franchise—Just Pipeline Risk
Verastem, Inc. has no true Dog in the BCG Matrix because it reported 0 marketed brands and 0 product revenue in FY2025 and FY2026. With no approved commercial product, there is no weak legacy franchise to harvest, divest, or fix. The core risk is pipeline execution, not declining sales. Year-end 2025 cash and equivalents were about $144 million, supporting R&D.
| Metric | FY2025/FY2026 |
|---|---|
| Marketed brands | 0 |
| Product revenue | 0 |
| Year-end cash | $144M |
| Dog status | None |
Question Marks
RAMP 202, KRAS and BRAF NSCLC
RAMP 202 is a Phase 2 study of VS-6766 plus defactinib in KRAS- and BRAF-mutant non-small cell lung cancer after platinum and immune checkpoint therapy. NSCLC is the largest lung cancer segment, with about 2.48 million new cases worldwide in 2022, so the addressable pool is sizable. But Verastem, Inc. still has low share here because the asset is investigational and not yet approved.
RAMP 203, LUMAKRAS combination
RAMP 203 is Verastem, Inc.’s Phase 1/2 test of VS-6766 with Amgen’s LUMAKRAS (sotorasib), so it fits a Question Mark in the BCG Matrix: high scientific interest, but no proven commercial scale yet. In targeted KRAS oncology, early-stage combos can create upside, but until efficacy and safety data mature, the revenue case stays uncertain.
Broader KRAS-mutant solid tumors
Verastem, Inc. can reach more than one KRAS-driven setting because KRAS mutations show up in about 25% of solid tumors, so the biology gives real upside beyond ovarian cancer. That makes this a question mark with strong growth optionality.
Still, each new tumor type must prove response, safety, and durability in its own cohort before it can win share. In KRAS-heavy cancers like NSCLC, KRAS G12C alone appears in about 13% of cases, but broad use needs better data than a mutation label.
So the asset can move from question mark to star only if late-stage readouts show clear, durable benefit and clean tolerability.
Defactinib combination expansion
Defactinib is still a Question Mark in Verastem, Inc.'s BCG Matrix because it works as a combination backbone, not as a standalone seller. Its 2025 FDA-accepted role came only with avutometinib in KRAS-mutated recurrent low-grade serous ovarian cancer, so growth depends on combo data holding up across more tumors. If new trials expand beyond one approved use, this could shift fast.
- 2025 approval supports combo value.
- Standalone market remains unproven.
- Broader tumor data is the key catalyst.
VS-6766 global expansion path
Chugai’s rights to develop and commercialize VS-6766 in Japan point to a wider global runway, not just a single-region story. The asset can scale, but only if late-stage clinical data and regulators back it. Until then, it stays a question mark, not a cash engine.
- Japan rights widen market reach
- Value still hinges on trial success
- No durable franchise cash flow yet
Verastem’s Oncology Bets: Big Upside, Still Unproven
Verastem, Inc.'s Question Marks are still early, high-upside oncology assets: RAMP 202 and RAMP 203 are both investigational, so share and revenue are not proven yet. The prize is big because KRAS mutations appear in about 25% of solid tumors, but each tumor type still needs its own win.
| Asset | 2025/2026 status | Why Question Mark |
|---|---|---|
| RAMP 202 | Phase 2 | No approval; NSCLC is huge but unproven |
| RAMP 203 | Phase 1/2 | Early combo; no scale yet |
| Defactinib | 2025 combo role | Value depends on more tumor data |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.